Crossmark

[Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV

Crossref DOI link: https://doi.org/10.1016/j.farma.2024.02.016

Published Print: 2024-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Martín-Zaragoza, Lorena

Sánchez-Rubio-Ferrández, Javier

Onteniente-González, Alberto

Gómez-Bermejo, Marcos

Rodríguez-Álvarez, Sergio Julio

Monereo-Alonso, Alfonso

Molina-García, Teresa
License Information

Text and Data Mining valid from 2024-07-01

Text and Data Mining valid from 2024-07-01

Version of Record valid from 2024-04-13
More Information

This article is maintained by: Elsevier

Article Title: [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV

Journal Title: Farmacia Hospitalaria

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.farma.2024.02.016

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.farma.2024.02.002

Content Type: article

Copyright: © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below